Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience

被引:10
作者
Castaman, Giancarlo [1 ]
Linari, Silvia [1 ]
Pieri, Lisa [1 ]
Carulli, Christian [2 ]
Prosperi, Paolo [3 ]
Tonelli, Paolo [4 ]
Demartis, Francesco [1 ]
Fjerza, Rajmonda [1 ]
Attanasio, Monica [1 ]
Coppo, Mirella [1 ]
Salvianti, Francesca [1 ]
机构
[1] Careggi Univ Hosp, Ctr Bleeding Disorders & Coagulat, Dept Oncol, I-50134 Florence, Italy
[2] Univ Hosp Florence, Dept Orthoped Surg, I-50139 Florence, Italy
[3] Careggi Univ Hosp, Emergency Surg Dept, I-50134 Florence, Italy
[4] Univ Florence, Dept Surg & Translat Med, I-50121 Florence, Italy
关键词
hemophilia A; FVIII inhibitors; FVIII concentrates; recombinant FVIIa; aPCC; prophylaxis; BISPECIFIC ANTIBODY; PROPHYLAXIS;
D O I
10.3390/jcm12062317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach provides constant protection, with significant reduction in bleeding rate and improved quality of life. However, protection provided by emicizumab is not absolute, and clotting factor concentrates (FVIII, rFVIIa, aPCC) may be necessary for post-traumatic bleeding or surgery, with a potential thrombotic risk or difficulty in preventing bleeding. Real world evidence is still scanty, especially for managing major surgery. In this study, 75 surgeries were managed in 28 patients (27 major procedures in 15 patients and 48 minor procedures in 20 patients. In 17 patients without inhibitors, 30 minor surgeries were carried out by using FVIII in 5, with only a bleeding event, which was successfully treated with FVIII concentrate. Six major surgeries were uneventfully performed with FVIII concentrate. Eleven PWHA and high-titer inhibitors underwent 39 surgical procedures (18 minor and 21 major surgeries). Minor surgeries were mostly performed without prophylaxis with rFVIIa, with only a single bleeding complication. All 21 major surgeries were covered with a homogeneous protocol using rFVIIa. In four instances, bleeding complications occurred, treated with rFVIIa. Of them, a single patient only failed to respond and died because of an uncontrollable bleeding from a large ruptured retroperitoneal pseudotumor. Surgery in patients with emicizumab can be safely carried out with the use of appropriate replacement therapy protocols.
引用
收藏
页数:12
相关论文
共 21 条
[1]   Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring [J].
Barg, Assaf A. ;
Budnik, Ivan ;
Avishai, Einat ;
Brutman-Barazani, Tami ;
Bashari, Dalia ;
Misgav, Mudi ;
Lubetsky, Aaron ;
Kuperman, Amir A. ;
Livnat, Tami ;
Kenet, Gili .
HAEMOPHILIA, 2021, 27 (03) :383-391
[2]   Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies [J].
Callaghan, Michael U. ;
Negrier, Claude ;
Paz-Priel, Ido ;
Chang, Tiffany ;
Chebon, Sammy ;
Lehle, Michaela ;
Mahlangu, Johnny ;
Young, Guy ;
Kruse-Jarres, Rebecca ;
Mancuso, Maria Elisa ;
Niggli, Markus ;
Howard, Monet ;
Bienz, Nives Selak ;
Shima, Midori ;
Jimenez-Yuste, Victor ;
Schmitt, Christophe ;
Asikanius, Elina ;
Levy, Gallia G. ;
Pipe, Steven W. ;
Oldenburg, Johannes .
BLOOD, 2021, 137 (16) :2231-2242
[3]   Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET [J].
Castaman, Giancarlo ;
Santoro, Cristina ;
Coppola, Antonio ;
Mancuso, Maria E. ;
Santoro, Rita C. ;
Bernardini, Sergio ;
Pugliese, Francesco R. ;
Lubrano, Riccardo ;
Golato, Maria ;
Tripodi, Armando ;
Rocino, Angiola ;
Santagostino, Elena .
BLOOD TRANSFUSION, 2020, 18 (02) :143-151
[4]   Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET [J].
Coppola, Antonio ;
Castaman, Giancarlo ;
Santoro, Rita C. ;
Mancuso, Maria Elisa ;
Franchini, Massimo ;
Marino, Renato ;
Rivolta, Gianna Franca ;
Santoro, Cristina ;
Zanon, Ezio ;
Sciacovelli, Laura ;
Manca, Salvatore ;
Lubrano, Riccardo ;
Golato, Maria ;
Tripodi, Armando ;
Rocino, Angiola .
HAEMOPHILIA, 2020, 26 (06) :937-945
[5]   Identification of Seven Novel Mutations of F8C by DHPLC [J].
Frusconi, Sabrina ;
Passerini, Ilaria ;
Girolami, Francesca ;
Masieri, Maddalena ;
Linari, Silvia ;
Longo, Giovanni ;
Morfini, Massimo ;
Torricelli, Francesca .
HUMAN MUTATION, 2002, 20 (03) :231-232
[6]   Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery [J].
Jimenez-Yuste, Victor ;
Carlos Rodriguez-Merchan, E. ;
Matsushita, Tadashi ;
Andre Holme, Pal .
HAEMOPHILIA, 2021, 27 (04) :519-530
[7]   Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies [J].
Kruse-Jarres, Rebecca ;
Peyvandi, Flora ;
Oldenburg, Johannes ;
Chang, Tiffany ;
Chebon, Sammy ;
Doral, Michelle Y. ;
Croteau, Stacy E. ;
Lambert, Thierry ;
Kempton, Christine L. ;
Pipe, Steven W. ;
Ko, Richard H. ;
Trzaskoma, Benjamin ;
Dhalluin, Christophe ;
Bienz, Nives Selak ;
Niggli, Markus ;
Lehle, Michaela ;
Paz-Priel, Ido ;
Young, Guy ;
Jimenez-Yuste, Victor .
BLOOD ADVANCES, 2022, 6 (24) :6140-6150
[8]   Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? [J].
Lenting, Peter J. ;
Denis, Cecile V. ;
Christophe, Olivier D. .
BLOOD, 2017, 130 (23) :2463-2468
[9]   Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program [J].
Levy, Gallia G. ;
Asikanius, Elina ;
Kuebler, Peter ;
El Fegoun, Soraya Benchikh ;
Esbjerg, Sille ;
Seremetis, Stephanie .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (09) :1470-1477
[10]   Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US [J].
Lewandowska, Magdalena ;
Randall, Nicole ;
Bakeer, Nihal ;
Maahs, Jennifer ;
Sagar, Jeanne ;
Greist, Anne ;
Shapiro, Amy D. .
HAEMOPHILIA, 2021, 27 (01) :90-99